Latest

2 stories

Hide weekly roundups

Monday, August 31

FDA accepts BLA for Alvotech's AVT80, a subcutaneous Entyvio biosimilar candidate

The filing covers a proposed interchangeable biosimilar to vedolizumab in prefilled syringe and autoinjector form, adding to Alvotech's intravenous candidate AVT16.

SEC filing

Friday, August 21

PartnershipAlvotech

Alvotech signs licensing deal with Lotus Pharmaceutical for two biosimilars

The deal covers proposed biosimilars to Imfinzi and Hemlibra in the U.S. and eight Asian markets, with potential value to Alvotech of up to about $150 million.

SEC filing